Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 2/20 | 0.44 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506476 | 0.80 | NCF1 (1.00) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| Ammonia Solution, Strong SCHEMBL6619954 | 0.80 | NCF1 (0.56) | NCF1MAPTCYP1A2NPC1RAB9A | |
| SCHEMBL12199211 | 0.80 | NCF1 (0.56) | NCF1MAPTCYP1A2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL7399656 | 0.78 | NCF1 (0.95) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL15842393 | 0.78 | NCF1 (0.95) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| SCHEMBL10458402 | 0.78 | NCF1 (0.71) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| SCHEMBL30760998 | 0.78 | NCF1 (0.71) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| SCHEMBL29652203 | 0.76 | NCF1 (0.57) | NCF1MAPTCYP1A2NPC1RAB9A | |
| SCHEMBL30223449 | 0.76 | PDGFRB (0.55) | ATMNPC1RAB9AKDM4EKMT2A | |
| SCHEMBL18232974 | 0.76 | PDGFRB (0.55) | ATMNPC1RAB9AKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024125668-A1 | HETEROCYCLIC SUBSTITUTED PENTA-SIX-MEMBERED HETEROARYL DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION AND PREPARATION METHOD THEREFOR | 上海海雁医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10738035-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10226535-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-9783500-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | NCF1 2242/4885ATM 3863/4885MAPT 4226/4885 |
| US-10226535-B2 | Auristatin compounds and conjugates thereof | PBRM1, AURKB, ILK | NCF1 3680/4885ATM 1666/4885MAPT 1644/4885 |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | NCF1 1330/4885ATM 2077/4885MAPT 2432/4885 |
| US-10738035-B2 | Hepatitis B antiviral agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | NCF1 1091/4885ATM 4841/4885MAPT 4734/4885 |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | NCF1 3978/4885ATM 3295/4885MAPT 809/4885 |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NOS2, NOS3, NOS1 | NCF1 633/4885ATM 2900/4885MAPT 882/4885 |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | NCF1 2425/4885ATM 3836/4885MAPT 3807/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | NCF1 2425/4885ATM 3836/4885MAPT 3807/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | NCF1 1330/4885ATM 2077/4885MAPT 2432/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | NCF1 1474/4885ATM 3400/4885MAPT 375/4885 |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | NCF1 1091/4885ATM 4841/4885MAPT 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.